APOL1 Variants Increase Risk for FSGS and HIVAN but Not IgA Nephropathy

Natalia Papeta,* Krzysztof Kiryluk,* Ami Patel,* Roel Sterken,* Nilgun Kacak,* Holly J. Snyder,* Phil H. Imus,* Anand N. Mhatre,† Anil K. Lawani,† Bruce A. Julian,‡ Robert J. Wyatt,§ Jan Novak,‡ Christina M. Wyatt,‖ Michael J. Ross,‖ Jonathan A. Winston,‖ Mary E. Klotman,¶ David J. Cohen,* Gerald B. Appel,* Vivette D. D'Agati,** Paul E. Klotman,†† and Ali G. Gharavi*

Departments of *Medicine and **Pathology, Columbia University College of Physicians and Surgeons, New York, New York; †Laboratory of Molecular Genetics, Department of Otolaryngology, New York University School of Medicine, New York, New York; ‡Departments of Microbiology and Medicine, University of Alabama at Birmingham, Birmingham, Alabama; §Children's Foundation Research Center at the Le Bonheur Children's Hospital, and the Division of Pediatric Nephrology, University of Tennessee Health Sciences Center, Memphis, Tennessee; ‖Department of Medicine, Mount Sinai School of Medicine, New York, New York, ¶Department of Medicine, Duke University School of Medicine, Durham, North Carolina; and ††Department of Medicine, Baylor College of Medicine, Houston, Texas

ABSTRACT

A chromosome 22q13 locus strongly associates with increased risk for idiopathic focal segmental glomerulosclerosis (FSGS), HIV-1-associated nephropathy (HIVAN), and hypertensive ESRD among individuals of African descent. Although initial studies implicated *MYH9*, more recent analyses localized the strongest association within the neighboring *APOL1* gene. In this replication study, we examined the six top-most associated variants in *APOL1* and *MYH9* in an independent cohort of African Americans with various nephropathies (44 with FSGS, 21 with HIVAN, 32 with IgA nephropathy, and 74 healthy controls). All six variants associated with FSGS and HIVAN (additive ORs, 1.8 to 3.0; *P* values 3×10^{-2} to 5×10^{-5}) but not with IgA nephropathy. In conditional and haplotype analyses, two *APOL1* haplotypes accounted for virtually all of the association with FSGS and HIVAN on chromosome 22q13 (haplotype *P* value $= 5.6 \times 10^{-8}$). To assess the role of MYH9 deficiency in nephropathy, we crossbred *Myh9*-haploinsufficient mice ($Myh9^{+/-}$) with HIV-1 transgenic mice. $Myh9^{+/-}$ mice were healthy and did not demonstrate overt proteinuria or nephropathy, irrespective of the presence of the HIV-1 transgene. These data further support the strong association of genetic variants in *APOL1* with susceptibility to FSGS and HIVAN among African Americans.

J Am Soc Nephrol 22: 1991–1996, 2011. doi: 10.1681/ASN.2011040434

African Americans have a three- to four-fold increased risk of focal segmental glomerulosclerosis (FSGS), HIV-associated nephropathy (HIVAN, a secondary form of FSGS associated with HIV infection), and nondiabetic ESRD compared with European-Americans.[1–4] Family members of African Americans with ESRD also have a higher incidence of kidney failure, suggesting that genetic susceptibility in part accounts for this skewed epidemiology.[5,6] In 2008, two independent studies demonstrated that variants on chromosome 22q13 were highly associated with the risk of FSGS, HIVAN, and nondiabetic ESRD among African Americans and explained much of the increased risk of kidney failure in this population (per alleles odds ratios [ORs] of 3 to 4).[7,8] Initially, *MYH9* was considered as the likely causal gene in this interval because it encodes a podocyte cytoskeletal protein and because *MYH9* coding mutations cause rare Mendelian disorders with occasional glomerulopathy. Follow-up studies confirmed and refined the signal within the *MYH9* locus,[9–11] but most recently, a comprehensive analysis of the chromosome 22q13 interval indicated that the association signal originated in the neighboring *APOL1* gene, and protein-altering variants (named G1 and G2) on two independent *APOL1* haplotypes explained all of the associations in this region.[12–14] The G1 haplotype encodes two linked missense variants (*P*.S342G and *P*.I384M), and the G2 haplotype encodes a two-amino-acid deletion (*P*.N388_Y389del) within the APOL1 carboxy-terminal domain; these variants are protective against *Trypanosoma brucei rhod-*

Received April 30, 2011. Accepted July 10, 2011.

Published online ahead of print. Publication date available at www.jasn.org.

Correspondence: Dr. Ali G. Gharavi, Department of Medicine, Columbia University College of Physicians and Surgeons, 1150 Street Nicholas Avenue, Russ Berrie Pavilion, Room 412, New York, New York 10032. Phone: 212-851-5556; Fax: 212-305-5520; E-mail: ag2239@columbia.edu

esiense infection and therefore provide an evolutionary advantage in Africa where this parasite is an endemic cause of sleeping sickness. Accordingly, these nephropathy risk alleles harbor signatures of positive selection and are very common on African American chromosomes but absent from European chromosomes.

To date, a direct comparison of the most significantly associated single-nucleotide polymorphisms (SNPs) in *MYH9* and *APOL1* has not been performed in independent cohorts, and the association of *APOL1* variants in the subgroups of HIVAN and IgA nephropathy (IgAN) has not been examined. Such replication studies are important for validation of genome-wide association studies and determination of the magnitude of risk imparted on different traits. In addition, examination of candidate genes in relevant animal models can provide biologic validation for statistical association in humans. In this study, we examined the most significantly associated SNPs in *MYH9* and *APOL1* in independent African American cohorts with FSGS, HIVAN, and IgAN. Next, we evaluated the effects of *Myh9* haploinsufficiency on the development of nephropathy using a validated mouse model of HIVAN.

In a human association study, we analyzed 32 patients with IgAN, 44 patients with FSGS, and 21 patients with HIVAN against a group of 74 healthy control individuals. All of the participants were of African American ancestry. We genotyped the six most significantly associated SNPs in *APOL1* (rs73885319 and rs60910145 for the G1 risk allele and rs71785313 for the G2 risk allele)[12] and *MYH9* (rs11912763, rs4821481, and rs5750250 tagging the F-1, E-1, and S-1 haplotypes, respectively).[7–11] Power analysis demonstrated that the IgAN cohort and the combined HIVAN and FSGS cohort provided >90% power to detect additive ORs >3.0 at two-sided alpha of 0.05 (Supplemental Table 1). All SNPs were in Hardy-Weinberg equilibrium in controls, and their allele frequencies did not differ from those reported in HapMap or other African American control populations.[12,15,16] After standard genotype quality control (see the Concise Methods section), we conducted association testing using a simple allelic test for each patient-control cohort (Table 1). None of the SNPs in *APOL1* or *MYH9* were associated with the risk of IgAN under an additive or a recessive model. In contrast, and consistent with previously reported data, five SNPs were significantly associated with the risk of FSGS (allelic ORs, 1.6 to 2.9) and HIVAN (allelic ORs, 2.1 to 3.4). Moreover, when the FSGS and HIVAN groups were combined, all six SNPs were significantly associated with risk of disease (allelic ORs, 1.8 to 3.0; *P* values, 3×10^{-2} to 5×10^{-5}; Table 1). Interestingly, the two most-significant SNPs (rs60910145 and rs11912763) reside in *APOL1* and *MYH9*, respectively, and thus the single SNP analysis could not clearly resolve the origin of the signal.

We performed a careful examination of the linkage disequilibrium (LD) structure among the six variants (Supplemental Table 2). The two *APOL1* G1-defining SNPs (rs73885319 and rs60910145) were in tight but imperfect LD ($r^2 = 0.924$, $D' = 0.98$) and were also in LD with the G2-defining SNP (rs71785313, $r^2 = 0.13$, $D' = 1$).[12] The complete LD between the G1- and G2-defining SNPs ($D' = 1$) is consistent with the presence of two mutually exclusive haplotypes at this locus. The three *MYH9* variants were in partial LD with *APOL1* variants ($r^2 = 0.02$ to 0.4, $D' = 0.725$ to 0.9). These data are consistent with prior reports of the LD structure of this region.

To better resolve the signal at this interval, we performed haplotype analysis with two- and three-SNP moving windows (Figure 1A). This analysis clearly localized the most significant signal within the *APOL1* locus: the association statistics within *APOL1* are within the threshold of genome-wide significance for genome-wide association studies and are nearly 4 orders of magnitude more significant compared with signals within the *MYH9* locus (peak two-SNP haplotype *P* values = 5.6×10^{-8} in *APOL1 versus* 2.7×10^{-4} in *MYH9* [Figure 1A and Supplemental Table 3]). Analysis of three-SNP haplotypes within *APOL1* confirmed that the G1 and G2 alleles reside on mutually exclusive haplotypes, and each confers independent risk of dis-

Table 1. Results of single SNP association analysis

Chr	SNP	Position (kb)	Minor Allele	MAF Controls	IgAN (35 Cases and 74 Controls)			FSGS (44 Cases and 74 Controls)			HIVAN (21 Cases and 74 Controls)			FSGS + HIVAN (65 Cases and 74 Controls)		
					MAF Cases	OR[a]	*P*[b]	MAF Cases	OR[a]	*P*[b]	MAF Cases	OR[a]	*P*[b]	MAF Cases	OR[a]	*P*[b]
22	rs73885319	36,661	G	0.264	0.214	0.76	0.43 (NS)	0.500	2.80	2.3×10^{-4}	0.455	2.33	1.6×10^{-2}	0.492	2.71	8.1×10^{-5}
22	rs60910145	36,662	G	0.250	0.214	0.82	0.56 (NS)	0.489	2.87	1.8×10^{-4}	0.455	2.50	9.1×10^{-3}	0.485	2.82	4.8×10^{-5}
22	rs71785313	36,662	Del	0.135	0.200	1.60	0.22 (NS)	0.250	2.13	2.6×10^{-2}	0.250	2.13	6.9×10^{-2}	0.246	2.09	1.8×10^{-2}
22	rs11912763	36,684	A	0.182	0.229	1.33	0.42 (NS)	0.386	2.82	5.4×10^{-4}	0.432	3.41	6.7×10^{-4}	0.400	2.99	6.0×10^{-5}
22	rs4821481	36,696	T	0.324	0.353	1.14	0.68 (NS)	0.227	0.61	1.1 × 10–1	0.159	0.39	3.3×10^{-2}	0.208	0.55	2.9×10^{-2}
22	rs5750250	36,708	A	0.439	0.441	1.01	0.98 (NS)	0.256	0.44	5.1×10^{-3}	0.182	0.28	2.0×10^{-3}	0.231	0.38	2.6×10^{-4}

IgAN, IgA nephropathy; FSGS, focal segmental glomerulosclerosis; HIVAN, HIV-1-associated nephropathy; Chr, chromosome; SNP, single-nucleotide polymorphism; MAF, minor allele frequency; NS, not significant.

[a]OR corresponds to the odds ratio per one copy of the minor allele. [b]*P* value corresponds to the allelic test of association.

ease (per haplotype ORs = 3.8 to 4.0; Figure 1B). The results of stepwise conditional analysis further support these conclusions (Table 2). After conditioning on the most significant SNP (*APOL1* G1/ rs60910145), one *APOL1* SNP (G2/ rs71785313, OR = 3.56, $P = 3.9 \times 10^{-4}$) and one *MYH9* SNP (rs11912763, OR = 1.9, $P = 0.048$) remained significant. The residual association with rs11912763 is due to its LD with G2-defining SNP (Supplemental Table 2). After accounting for rs71785313, there were no other significant signals (Table 2). These data clearly indicate that the *APOL1* G1 and G2 variants explain all of the association observed with the *MHY9* SNPs.



B

	rs73885319	rs60910145	rs71785313	Freq. Cases:	Freq. Controls:	OR (95% CI):	Global Haplo Test:
	A	T	I	0.265	0.609	- reference -	
G1 →	G	G	I	0.486	0.245	3.83 (2.13-6.91)*	$p = 9.7 \times 10^{-8}$
G2 →	A	T	D	0.244	0.127	4.01 (1.91-8.43)*	
	G	T	I	0.005	0.018	0.80 (0.04-17.0)	

Figure 1. Haplotype analysis localized the most significant signal within the *APOL1* locus. (A) Two-SNP and three-SNP haplotype sliding-window analysis localized the strongest signal within the *APOL1* locus. The *y* axis shows the −log (*P* value) for the association statistic. The *x* axis shows the tested SNP and their location within the *APOL1* and *MYH9* genes. (B) Haplotype analysis of the *APOL1* SNPs demonstrated that G1 and G2 reside on distinct haplotypes and each confers an independent risk of disease compared with the reference haplotype. G1 is defined by the rs73885319-G and rs60910145-G alleles, and G2 is defined by the rs71785313 deletion allele (D). The odds ratios (ORs) were calculated in reference to the most common haplotype, which does not contain any risk variants (ATI). **P* value <0.05 *versus* the reference haplotype. The *P* value for the global haplotype test is also indicated.

Because the *APOL1* G1 and G2 haplotypes confer a comparable risk of disease but reside on distinct haplotypes (Figure 1B), we recoded rs60910145 and rs71785313 into a single locus, where each individual was considered to harbor 0, 1, or 2 *APOL1* risk alleles (*i.e.* G1/+ and G2/+ genotypes were coded as heterozygotes, and G1/G1, G1/G2, and G2/G2 genotypes were coded as homozygotes). In this analysis, additive and recessive models were similarly supported and reached thresholds for genome-wide significance ($OR_{ADD} = 3.89$, $P_{ADD} = 5 \times 10-^{8}$ and $OR_{REC} = 10.9$, $P_{REC} = 1 \times 10^{-9}$). Because eight individuals with FSGS or HIVAN did not carry any G1 or G2 alleles, we sequenced all *APOL1* exons in these individuals but did not identify any rare coding mutations that could account for disease. In other secondary analyses, we examined the effect of *APOL1* variants on the risk of renal failure and detected a suggestive association with increased risk of ESRD among the IgAN patients, but not among the FSGS/HIVAN cohorts (OR 3.2, $P = 0.049$; Supplemental Table 4).

In addition to the statistical evidence provided by human association studies, analysis of biologically relevant mouse models can provide independent assessment of candidate genes within association intervals. In this regard, we had previously shown that renal expression of *Myh9* is reduced by approximately 30% in HIV-1 transgenic mice on the susceptible FVB/NJ genetic background,[17] a validated model of HIVAN that exhibits proteinuria and classical features of collapsing glomerulopathy with cystic tubular dilation by 6 to 8 weeks of age.[18,19] However, we could not determine whether this reduced expression played a direct role in the pathogenesis of disease or represented a secondary consequence of glomerulosclerosis. Homozygous inactivation of *Myh9* results in embryonic lethality at embryonic day 6.5, but *Myh9* haploinsufficient mice ($Myh9^{+/-}$), despite significantly reduced MYH9 protein level, are born normally and do not develop gross organ dysfunction.[20,21] Therefore, we examined *Myh9* haploinsufficient mice

Table 2. Stepwise conditional association analyses of *APOL1* and *MYH9* variants in the combined cohort of HIVAN and FSGS (65 cases and 74 controls)

Chr	SNP	Tested Allele	Conditioning SNP: Not Conditioned OR[a]	Not Conditioned P[b]	rs60910145 OR[a]	rs60910145 P[b]	rs60910145 and rs71785313 OR[a]	rs60910145 and rs71785313 P[b]
22	rs73885319	G	2.71 (1.64 to 4.48)	$8.1 \times 10^{-5***}$	1.34 (0.21 to 8.52)	0.76 (NS)	1.74 (0.26 to 11.8)	0.57 (NS)
22	rs60910145	G	2.82 (1.70 to 4.68)	$4.8 \times 10^{-5***}$				
22	rs71785313	Del	2.09 (1.13 to 3.88)	0.018*	3.71 (1.80 to 7.66)	$3.9 \times 10^{-4***}$		
22	rs11912763	A	2.99 (1.73 to 5.15)	$6.0 \times 10^{-5***}$	2.03 (1.01 to 4.09)	0.048*	1.95 (0.94 to 4.03)	0.074 (NS)
22	rs4821481	C	1.83 (1.06 to 3.16)	0.029*	0.90 (0.48 to 1.67)	0.73 (NS)	1.57 (0.75 to 3.26)	0.23 (NS)
22	rs5750250	G	2.61 (1.55 to 4.40)	$2.6 \times 10^{-4***}$	0.57 (0.33 to 1.01)	0.055 (NS)	0.98 (0.49 to 1.94)	0.95 (NS)

Chr, chromosome; SNP, single-nucleotide polymorphism; NS, not significant.
[a]OR corresponds to the conditioned odds ratio per one copy of the minor allele.
[b]P value corresponds to the conditional test of association under additive allele coding.
*$P < 0.05$; ***$P < 0.001$.

($Myh9^{+/-}$) and crossbred them with HIV-1 transgenic mice on the C57BL/6J (B6) genetic background. We chose the B6 background because it is protective against HIV-1 nephropathy in mice[22,23]; consequently, this breeding scheme could clearly determine whether a primary reduction in MYH9 expression, in conjunction with a biologically relevant stressor, would overcome genetic resistance and produce kidney disease.



Figure 2. Myh9 haploinsufficiency does not induce nephropathy in HIV-1 transgenic mice. (A-C) Renal histology (Periodic acid-Schiff staining) was normal in B6 (A), B6-$Myh9^{+/-}$ (B), and TgB6-$Myh9^{+/-}$ (C) mice. (D) Proteinuria (quantified as μg of albumin/mg of creatinine ratio in urine) was increased in the *Myh9* haploinsufficient, HIV transgenic mice (TgB6-$Myh9^{+/-}$) compared with the B6 and B6-$Myh9^{+/-}$ parental strains but was still within the range of normal for inbred mice (*e.g.* DBA/2J or FVB/NJ). n = four to five mice per group.

We assessed renal histopathology at 5 to 6 months of age (19 to 29 mice per group; Figure 2) and quantified urine protein levels using an albumin-to-creatinine ratio in a random subset (four to five mice per group). As previously reported, $Myh9^{+/-}$ mice and HIV-1 transgenic mice on the B6 genetic background were free of kidney disease, and their urinary albumin levels and renal histology scores did not differ from wild-type B6 mice.[20,21,22,23] HIV-1 transgenic $Myh9^{+/-}$ mice also did not have any detectable histopathologic evidence of nephropathy (Figure 2). These mice had a minor but statistically significant increase in albuminuria compared with parental strains (22.1 ± 3.7 *versus* 6.4 ± 2.8, $P = 0.02$; Figure 2), but this level of albuminuria was well within the range of normal variation for inbred strains (reported range 3 to 142 μg albumin/mg creatinine).[19,24,25] We confirmed that *Myh9* expression was significantly decreased (by 30%) in $Myh9^{+/-}$ mice compared with wild-type littermates (Supplemental Figure 1), which was comparable to the reduction observed in the TgFVB strain.[22] This suggests that reduced *Myh9* expression in the TgFVB strain occurs secondary to glomerulosclerosis and is likely not causal in the development of nephropathy.

In conclusion, analysis of the most significantly associated SNPs in *APOL1* and *MYH9* in independent human cohorts confirmed that *APOL1* haplotypes explain most of the association signal at the Chr. 22q13 locus, suggesting little or

no remaining effect of the *MYH9* locus on the risk of FSGS and HIVAN. These conclusions are further supported by the finding that *Myh9* haploinsufficiency alone does not cause kidney disease, and crossbreeding with a validated mouse model of HIVAN produces only a negligible increase in proteinuria. We also confirm that the *APOL1* G1 and G2 alleles are independent risk factors for FSGS and HIVAN, with a magnitude and direction of effects that was nearly identical to previously reported findings.[12,13] The *APOL1* variants did not impart the same large risk on IgAN, although we found a nominal association with increased risk of ESRD in this group, suggesting that *APOL1* risk alleles may play a role in progression of some glomerulopathies; these findings will require confirmation in larger cohorts. Contrary to prior studies, however, the current analysis did not clearly favor the recessive over the additive model and showed similar odds ratios for the risk of HIVAN and FSGS. This suggests that *APOL1*-associated FSGS and HIVAN do not conform to a simple Mendelian recessive model. Given the significant risk conferred by the G1 and G2 haplotypes, better delineation of the genetic model can facilitate the development and interpretation of *APOL1* genotyping as a predictive tool for nephropathy. In addition, about 12 to 15% of individuals with FSGS or HIVAN carry neither G1 nor G2 *APOL1* risk alleles,[12] suggesting that additional risk factors account for disease in this subgroup. Further investigation of *APOL1* and downstream pathways will likely clarify novel pathogenetic mechanisms common to various forms of nephropathy.

CONCISE METHODS

Human Studies

We recruited African American patients with biopsy-documented idiopathic FSGS, HIVAN, or IgAN. FSGS was diagnosed by the presence of focal and segmental glomerular lesions in a proteinuric patient without known secondary causes such as drug toxicity or sickle cell disease; HIVAN was defined by the finding of collapsing FSGS in the setting of HIV infection; IgAN was defined by mesangial proliferation combined with predominant glomerular IgA deposition on immunofluorescence. In total, we studied 32 patients with IgAN, 44 patients with idiopathic FSGS (including eight collapsing cases), and 21 patients with HIVAN, as well as a control group of 74 healthy African American individuals with no proteinuria on urine dipstick. Participants were recruited from three medical centers: Columbia University (New York, NY), Mount Sinai Medical Center (New York, NY), and University of Alabama (Birmingham, AL). The study protocol was approved by the Columbia University, University of Alabama at Birmingham, and Mount Sinai Medical Center Institutional Review Board committees.

Genomic DNA was isolated from blood using DNeasy kit (Qiagen). We selected SNPs with the strongest reported associations in *APOL1*[12,13] and *MYH9*[9,10] and genotyped them by direct Sanger sequencing. The PCR primer sequences used are provided in Supplemental Table 5. The genotypes were called by using the SEQUENCHER software (GeneCodes). Genotyping accuracy was confirmed by bidirectional sequencing in approximately 10% of individuals. All of the genotypes underwent standard quality control procedures before association analysis: all SNPs had >99% genotyping rates, and all passed the Hardy-Weinberg equilibrium test in controls (P value >0.05).

We performed a standard allelic test of association using PLINK v.1.07.[26] We estimated the per-allele odds ratios and 95% confidence intervals for all tested SNPs. We calculated the pairwise LD statistics (r^2 and D') for all analyzed SNPs after estimating haplotype frequencies using the EM algorithm. In the conditional analyses, we controlled for the genotypes of the conditioning SNPs using logistic regression under additive and recessive models. Because this is a replication study, we report nominal two-sided P values and considered P values <0.05 as significant. A Bonferroni adjustment for multiple testing can be obtained by multiplying P values by 6 (the number of SNPs tested in this study), but this would be an overly stringent correction because these loci are not independent (Supplemental Table 2).

The haplotypes were phased using the EM algorithm as implemented in PLINK v.1.07[26]; the haplotype frequencies were estimated in the patients and controls separately, as well as jointly in the entire cohort, to detect the likelihood of a true difference in frequency between patients and controls. Only the haplotypes with the overall frequency greater than 1% were included in association analyses. The odds ratios and the corresponding 95% confidence intervals were estimated in reference to the most common haplotype that carried no putative risk alleles.

Mouse Studies

Myh9 haploinsufficient mice ($Myh9^{+/-}$) have been previously characterized in detail.[21] The mice were maintained by backcrossing to B6 at Columbia University. For the HIV-1 transgenic mouse line, we backcrossed the well-characterized TgN (pNL43d14)26Lom 26 mice[27] to B6 mice for at least seven generations to generate heterozygous HIV-1 transgenic strain on the B6 genetic background (TgB6). We confirmed that both $Myh9^{+/-}$ and TgB6 mice had a homogeneous B6 background by genotyping 82 informative loci across the genome (Kbioscience, Hoddesdon, UK). *Myh9* haploinsufficient mice ($Myh9^{+/-}$, $n = 29$) were compared with wild-type littermates (B6, $n = 23$), TgB6 mice ($n = 19$), and $Myh9^{+/-}$TgB6 ($n = 19$) mice at 5 to 6 months of age. The animal protocol was approved by the institutional animal care and use committee at Columbia University.

Total RNA was extracted from mouse kidneys using TRIzol reagent (Invitrogen) followed by treatment with DNaseI and cleanup using the RNeasy kit (Qiagen) according to the manufacturers' protocols. cDNA was generated with the Omni-Script kit (Qiagen). Gene expression was quantitated by quantitative PCR using SYBR-Green mix and IQ5 thermal Cycler (Bio-Rad). *β-actin* was used as a housekeeping control.

We used albumin-to-creatinine ratio (Albuwell M and creatinine ELISA kits; Exocell) for quantification of urine albumin in a random subset (four to five mice in each genotype group). The degree of renal injury was evaluated by examination of kidney histopathology (Periodic acid-Schiff staining). Pathologic evaluation included the severity of tubulointerstitial disease (tubular casts, tubular dilation, and epithelial regeneration/degeneration), as well as the type and extent of glomerular injury (segmental and global glomerulosclerosis and collapse, podocyte hyperplasia, and collapse).

ACKNOWLEDGMENTS

This study was supported by National Institutes of Health Grants DK087626 (to A.G.G.), DK082753 (to A.G.G. and J.N.), and DK056492 (to P.E.K.), the Columbia Center for Glomerular Diseases, and the Daniel Midler Research Fund in Nephrology. K.K. is supported by National Institutes of Health Grant 1K23DK090207, and R.S. is supported by a fellowship from the Belgian-American Education Foundation.

DISCLOSURES

None.

REFERENCES

1. Kiberd BA, Clase CM: Cumulative risk for developing end-stage renal disease in the US population. *J Am Soc Nephrol* 13: 1635–1644, 2002
2. Tucker JK: Focal segmental glomerulosclerosis in African Americans. *Am J Med Sci* 323: 90–93, 2002
3. Kiryluk K, Martino J, Gharavi AG: Genetic susceptibility, HIV infection, and the kidney. *Clin J Am Soc Nephrol* 2[Suppl 1]: S25–S35, 2007
4. Papeta N, Sterken R, Kiryluk K, Kalyesubula R, Gharavi AG: The molecular pathogenesis of HIV-1 associated nephropathy: Recent advances. *J Mol Med* 89: 429–436, 2011
5. Wyatt CM, Klotman PE: HIV-associated nephropathy in the era of antiretroviral therapy. *Am J Med* 120: 488–492, 2007
6. Freedman BI, Soucie JM, Stone SM, Pegram S: Familial clustering of end-stage renal disease in blacks with HIV-associated nephropathy. *Am J Kidney Dis* 34: 254–258, 1999
7. Kao WH, Klag MJ, Meoni LA, Reich D, Berthier-Schaad Y, Li M, Coresh J, Patterson N, Tandon A, Powe NR, Fink NE, Sadler JH, Weir MR, Abboud HE, Adler SG, Divers J, Iyengar SK, Freedman BI, Kimmel PL, Knowler WC, Kohn OF, Kramp K, Leehey DJ, Nicholas SB, Pahl MV, Schelling JR, Sedor JR, Thornley-Brown D, Winkler CA, Smith MW, Parekh RS: MYH9 is associated with nondiabetic end-stage renal disease in African Americans. *Nat Genet* 40: 1185–1192, 2008
8. Kopp JB, Smith MW, Nelson GW, Johnson RC, Freedman BI, Bowden DW, Oleksyk T, McKenzie LM, Kajiyama H, Ahuja TS, Berns JS, Briggs W, Cho ME, Dart RA, Kimmel PL, Korbet SM, Michel DM, Mokrzycki MH, Schelling JR, Simon E, Trachtman H, Vlahov D, Winkler CA: MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. *Nat Genet* 40: 1175–1184, 2008
9. Nelson GW, Freedman BI, Bowden DW, Langefeld CD, An P, Hicks PJ, Bostrom MA, Johnson RC, Kopp JB, Winkler CA: Dense mapping of MYH9 localizes the strongest kidney disease associations to the region of introns 13 to 15. *Hum Mol Genet* 19: 1805–1815, 2010
10. Behar DM, Rosset S, Tzur S, Selig S, Yudkovsky G, Bercovici S, Kopp JB, Winkler CA, Nelson GW, Wasser WG, Skorecki K: African ancestry allelic variation at the MYH9 gene contributes to increased susceptibility to non-diabetic end-stage kidney disease in Hispanic Americans. *Hum Mol Genet* 19: 1816–1827, 2010
11. Shlush LI, Bercovici S, Wasser WG, Yudkovsky G, Templeton A, Geiger D, Skorecki K: Admixture mapping of end stage kidney disease genetic susceptibility using estimated mutual information ancestry informative markers. *BMC Med Genomics* 3: 47, 2010
12. Genovese G, Friedman DJ, Ross MD, Lecordier L, Uzureau P, Freedman BI, Bowden DW, Langefeld CD, Oleksyk TK, Uscinski Knob AL, Bernhardy AJ, Hicks PJ, Nelson GW, Vanhollebeke B, Winkler CA, Kopp JB, Pays E, Pollak MR: Association of trypanolytic ApoL1 variants with kidney disease in African Americans. *Science* 329: 841–845, 2010
13. Genovese G, Tonna SJ, Knob AU, Appel GB, Katz A, Bernhardy AJ, Needham AW, Lazarus R, Pollak MR: A risk allele for focal segmental glomerulosclerosis in African Americans is located within a region containing APOL1 and MYH9. *Kidney Int* 78: 698–704, 2010
14. Tzur S, Rosset S, Shemer R, Yudkovsky G, Selig S, Tarekegn A, Bekele E, Bradman N, Wasser WG, Behar DM, Skorecki K: Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene. *Hum Genet* 128: 345–350, 2010
15. Kao WH, Klag MJ, Meoni LA, Reich D, Berthier-Schaad Y, Li M, Coresh J, Patterson N, Tandon A, Powe NR, Fink NE, Sadler JH, Weir MR, Abboud HE, Adler SG, Divers J, Iyengar SK, Freedman BI, Kimmel PL, Knowler WC, Kohn OF, Kramp K, Leehey DJ, Nicholas SB, Pahl MV, Schelling JR, Sedor JR, Thornley-Brown D, Winkler CA, Smith MW, Parekh RS: MYH9 is associated with nondiabetic end-stage renal disease in African Americans. *Nat Genet* 40: 1185–1192, 2008
16. Kopp JB, Smith MW, Nelson GW, Johnson RC, Freedman BI, Bowden DW, Oleksyk T, McKenzie LM, Kajiyama H, Ahuja TS, Berns JS, Briggs W, Cho ME, Dart RA, Kimmel PL, Korbet SM, Michel DM, Mokrzycki MH, Schelling JR, Simon E, Trachtman H, Vlahov D, Winkler CA: MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. *Nat Genet* 40: 1175–1184, 2008
17. Papeta N, Zheng Z, Schon EA, Brosel S, Altintas MM, Nasr SH, Reiser J, D'Agati VD, Gharavi AG: Prkdc participates in mitochondrial genome maintenance and prevents Adriamycin-induced nephropathy in mice. *J Clin Invest* 120: 4055–4064, 2010
18. Kopp JB, Klotman ME, Adler SH, Bruggeman LA, Dickie P, Marinos NJ, Eckhaus M, Bryant JL, Notkins AL, Klotman PE: Progressive glomerulosclerosis and enhanced renal accumulation of basement membrane components in mice transgenic for human immunodeficiency virus type 1 genes. *Proc Natl Acad Sci U S A* 89: 1577–1581, 1992
19. Chan KT, Papeta N, Martino J, Zheng Z, Frankel RZ, Klotman PE, D'Agati VD, Lifton RP, Gharavi AG: Accelerated development of collapsing glomerulopathy in mice congenic for the HIVAN1 locus. *Kidney Int* 75: 366–372, 2009
20. Conti MA, Even-Ram S, Liu C, Yamada KM, Adelstein RS: Defects in cell adhesion and the visceral endoderm following ablation of nonmuscle myosin heavy chain II-A in mice. *J Biol Chem* 279: 41263–41266, 2004
21. Mhatre AN, Li Y, Bhatia N, Wang KH, Atkin G, Lalwani AK: Generation and characterization of mice with Myh9 deficiency. *Neuromolecular Med* 9: 205–215, 2007
22. Papeta N, Chan KT, Prakash S, Martino J, Kiryluk K, Ballard D, Bruggeman LA, Frankel R, Zheng Z, Klotman PE, Zhao H, D'Agati VD, Lifton RP, Gharavi AG: Susceptibility loci for murine HIV-associated nephropathy encode trans-regulators of podocyte gene expression. *J Clin Invest* 119: 1178–1188, 2009
23. Zuo Y, Matsusaka T, Zhong J, Ma J, Ma LJ, Hanna Z, Jolicoeur P, Fogo AB, Ichikawa I: HIV-1 genes vpr and nef synergistically damage podocytes, leading to glomerulosclerosis. *J Am Soc Nephrol* 17: 2832–2843, 2006
24. Sheehan S, Tsaih SW, King BL, Stanton C, Churchill GA, Paigen B, DiPetrillo K: Genetic analysis of albuminuria in a cross between C57BL/6J and DBA/2J mice. *Am J Physiol Renal Physiol* 293: F1649–F1656, 2007
25. Doorenbos C, Tsaih SW, Sheehan S, Ishimori N, Navis G, Churchill G, Dipetrillo K, Korstanje R: Quantitative trait loci for urinary albumin in crosses between C57BL/6J and A/J inbred mice in the presence and absence of Apoe. *Genetics* 179: 693–699, 2008
26. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de Bakker PI, Daly MJ, Sham, P.C. PLINK: A tool set for whole-genome association and population-based linkage analyses. *Am J Hum Genet* 81: 559–575, 2007
27. Dickie P, Felser J, Eckhaus M, Bryant J, Silver J, Marinos N, Notkins AL: HIV-associated nephropathy in transgenic mice expressing HIV-1 genes. *Virology* 185: 109–119, 1991

See related editorial, "Apolipoprotein L1 and the Genetic Basis for Racial Disparity in Chronic Kidney Disease," on pages 1955–1958.

Supplemental information for this article is available online at http://www.jasn.org/.

Supplemental Table 1a. Power Analysis for the combined FSGS and HIVAN cohort. The power calculations assume a cohort of 65 cases and 74 controls, two-sided alpha 0.05, minor allele frequency 0.2, and baseline disease risk of 1%. Power calculations were conducted using Quanto v.1.2.4 software.

Additive OR	Study Power Additive Model
2.0	70.5%
3.0	98.1%
4.0	99.9%

Recessive OR	Study Power Recessive Model
4.0	57.3%
6.0	84.5%
8.0	95.1%

Supplemental Table 1b. Power Analysis for the IgAN cohort. The power calculations assume a cohort of 35 cases and 74 controls, two-sided alpha 0.05, minor allele frequency 0.2, and baseline disease risk of 1%.

Additive OR	Study Power Additive Model
2.0	55.1%
3.0	92.3%
4.0	98.9%

Recessive OR	Study Power Recessive Model
4.0	44.7%
6.0	72.3%
8.0	87.4%

Supplemental Table 2. Pairwise linkage disequilibrium measures between the markers tested: r^2 above the diagonal, D' below the diagonal. Both LD measures calculated based on a joint sample of 65 cases (HIVAN + FSGS) and 74 controls.

r^2 / D'		APOL1			MYH9		
		rs73885319	**rs60910145**	**rs71785313**	**rs11912763**	**rs4821481**	**rs5750250**
APOL1	**rs73885319**		0.924	0.135	0.354	0.174	0.180
	rs60910145	0.984		0.129	0.404	0.167	0.173
	rs71785313	1.000	1.000		0.016	0.037	0.096
MYH9	**rs11912763**	0.725	0.756	0.422		0.127	0.148
	rs4821481	0.895	0.898	0.664	0.931		0.592
	rs5750250	0.768	0.769	0.896	0.848	0.912	

Supplemental Table 3. Sliding Window Haplotype Analysis.

3-SNP window

SNP window	Haplotype	Freq. cases	Freq. controls	CHISQ	DF	Omnibus P-value
rs73885319 | rs60910145 | rs71785313	ATD	0.244	0.127	**35.46**	**3**	**9.7E-08**
	GGI	0.486	0.245			
	GTI	0.005	0.018			
	ATI	0.265	0.609			
rs60910145 | rs71785313 | rs11912763	TDA	0.041	0.001	**38.24**	**5**	**3.4E-07**
	GIA	0.332	0.158			
	TIA	0.027	0.024			
	TDG	0.206	0.134			
	GIG	0.152	0.092			
	TIG	0.242	0.591			
rs71785313 | rs11912763 | rs4821481	DGT	0.013	0.013	**25.22**	**5**	**1.3E-04**
	IGT	0.187	0.310			
	DAC	0.050	0.003			
	IAC	0.345	0.178			
	DGC	0.185	0.119			
	IGC	0.220	0.377			
rs11912763 | rs4821481 | rs5750250	GTA	0.185	0.311	**22.80**	**4**	**1.4E-04**
	GCA	0.036	0.117			
	GTG	0.016	0.016			
	ACG	0.393	0.166			
	GCG	0.369	0.390			

2-SNP window

SNP window	Haplotype	Freq. cases	Freq. controls	CHISQ	DF	Omnibus P-value
rs73885319 | rs60910145	GG	0.485	0.245	**17.52**	**2**	**1.6E-04**
	GT	0.008	0.020			
	AT	0.508	0.735			
rs60910145 | rs71785313	TD	0.246	0.135	**33.39**	**2**	**5.6E-08**
	GI	0.485	0.250			
	TI	0.269	0.615			
rs71785313 | rs11912763	DA	0.059	0.006	**24.60**	**3**	**1.9E-05**
	IA	0.341	0.176			
	DG	0.188	0.129			
	IG	0.413	0.689			
rs11912763 | rs4821481	GT	0.201	0.323	**16.41**	**2**	**2.7E-04**
	AC	0.395	0.181			
	GC	0.405	0.497			
rs4821481 | rs5750250	TA	0.192	0.311	**14.89**	**3**	**1.9E-03**
	CA	0.038	0.128			
	TG	0.015	0.014			
	CG	0.754	0.547			

I= insertion, D= deletion at rs71785313

Supplemental Table 4. Association analysis of *APOL1* and *MYH9* SNPs with risk of ESRD in IgAN patients.

SNP	BP	Allele	IgAN ESRD (N=9)	IgAN No ESRD (N=23)	OR	P-value
rs73885319	36661906	G	0.364	0.152	3.18	0.049 *
rs60910145	36662034	G	0.364	0.152	3.18	0.049 *
rs71785313	36662046	D	0.136	0.217	0.57	0.43
rs11912763	36684722	A	0.364	0.174	2.71	0.08
rs4821481	36695942	T	0.455	0.318	1.79	0.28
rs5750250	36708483	A	0.546	0.409	1.73	0.29

Supplemental Table 5. Primer sequences.

Gene	SNP	Forward primer	Reverse primer
APOL1	rs73885319 rs60910145 rs71785313	AGCTGAAAGCGGTGAACAG	CATATCTCTCCTGGTGGCTG
MYH9	rs11912763	GAGTCACTGAACCCCGAGAC	GAGCAGAGCGAGGAGAAGAAG
	rs4821481	TGAGGGCTTCTGCTTAACTG	AACCCCACAGTGACCAACAC
	rs5750250	GGCTGACACCTTTACCCAAG	ATCTCCCGTGGCAGGATC

Supplemental Figure 1. *Myh9* expression in whole kidney from B6 mice, *Myh9* haploinsufficient (B6-Myh9$^{+/-}$) and HIV transgenic mice (TgB6-Myh9$^{+/-}$) at 4-5 months of age. Expression is adjusted to a B6 sample, N = 4-5 per group. * $p<0.04$ vs. B6 mice.